利用高多重数字空间分析发现非小细胞肺癌免疫检查点阻断耐药生物标志物
研究采用NanoString GeoMx数字空间分析技术,对56例接受免疫检查点抑制剂(ICI)治疗的非小细胞肺癌(NSCLC)治疗前样本进行71种蛋白标志物检测,在四个分子区室中分析。发现CD45+CD68免疫间质区室中CD66b预测更短总生存(HR 1.31,p=0.016),并在额外39例ICI治疗及236例未接受ICI的可手术NSCLC患者中验证。结论认为CD66b表达提示ICI耐药,因CD66b标记中性粒细胞,需进一步研究中性粒细胞在ICI耐药中的作用。
要点
- CD45+CD68免疫间质区室中CD66b预测ICI治疗NSCLC患者总生存更短(HR 1.31,p=0.016)。
- 定量免疫荧光验证显示CD66b与ICI耐药相关,在未治疗NSCLC中无预后价值。
- CD66b标记中性粒细胞,其在ICI耐药中的作用需进一步研究。
核心结论
- CD66b表达提示NSCLC患者对ICI治疗耐药,因CD66b标记中性粒细胞,需进一步研究中性粒细胞在ICI耐药中的作用。
研究设计与样本
- 研究采用NanoString GeoMx数字空间分析方法,对56例接受ICI治疗的NSCLC患者治疗前样本进行蛋白检测。
- 使用71种光可裂解寡核苷酸标记的一抗在四个分子区室(肿瘤、白细胞、巨噬细胞、免疫间质)中检测蛋白。
- 另纳入39例接受ICI治疗及236例未接受ICI治疗的可手术NSCLC患者治疗前样本进行独立队列验证。
主要发现
- 基于蛋白的分子区室化策略可评估284个蛋白变量与ICI耐药的关联(单变量分析,连续对数缩放数据)。
- 71种候选蛋白标志物中,CD45+CD68分子区室(免疫间质)中CD66b预测总生存显著缩短(HR 1.31,p=0.016),被选为验证对象。
- 定量免疫荧光正交验证显示CD66b与ICI治疗耐药相关,但在未治疗NSCLC中无预后价值:发现队列OS HR 2.49(p=0.026),验证队列OS HR 2.05(p=0.046),非ICI治疗队列OS HR 1.67(p=0.06)。
关键数值与推荐
- CD66b在CD45+CD68免疫间质区室中预测总生存缩短:发现阶段HR 1.31(p=0.016)。
- 定量免疫荧光验证:发现队列OS HR 2.49(p=0.026),验证队列OS HR 2.05(p=0.046),非ICI治疗队列OS HR 1.67(p=0.06)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 因CD66b标记中性粒细胞,需进一步研究以明确中性粒细胞在ICI耐药中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite the clinical efficacy of immune checkpoint inhibitors (ICIs) in NSCLC, only approximately 20% of patients remain disease-free at 5 years. Here, we use digital spatial profiling to find candidate biomarker proteins associated with ICI resistance. METHODS: Pretreatment samples from 56 patients with NSCLC treated with ICI were analyzed using the NanoString GeoMx digital spatial profiling method. A panel of 71 photocleavable oligonucleotide-labeled primary antibodies was used for protein detection in four molecular compartments (tumor, leukocytes, macrophages, and immune stroma). Promising candidates were orthogonally validated with quantitative immunofluorescence. Available pretreatment samples from 39 additional patients with NSCLC who received ICI and 236 non-ICI-treated patients with operable NSCLC were analyzed to provide independent cohort validation. RESULTS: Biomarker discovery using the protein-based molecular compartmentalization strategy allows 284 protein variables to be assessed for association with ICI resistance by univariate analysis using continuous log-scaled data. Of the 71 candidate protein biomarkers, CD66b in the CD45+CD68 molecular compartment (immune stroma) predicted significantly shorter overall survival (OS) (hazard ratio [HR] 1.31, p = 0.016) and was chosen for validation. Orthogonal validation by quantitative immunofluorescence illustrated that CD66b was associated with resistance to ICI therapy but not prognostic for poor outcomes in untreated NSCLC (discovery cohort [OS HR 2.49, p = 0.026], validation cohort [OS HR 2.05, p = 0.046], non-ICI-treated cohort [OS HR 1.67, p = 0.06]). CONCLUSIONS: Using the technique, we have discovered that CD66b expression is indicative of resistance to ICI therapy in NSCLC. Given that CD66b identifies neutrophils, further studies are warranted to characterize the role of neutrophils in ICI resistance.
引用
- Moutafi M, Martinez-Morilla S, Divakar P, et al. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. J Thorac Oncol. 2022. PMID: 35490853. doi:10.1016/j.jtho.2022.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。